Johnson & Johnson (NYSE: JNJ) has taken legal action against Samsung Bioepis, accusing the South Korean biotech of violating ...
Janssen has sued Samsung Bioepis, alleging it violated a settlement agreement by authorizing an unauthorized Stelara® ...
MedImpact Healthcare Systems, the nation’s largest independent provider of health solutions, technology, and pharmacy benefit ...
Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...
Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
Biocon Biologics launches Yesintek biosimilar to Stelara in US: Our Bureau, Bengaluru Tuesday, February 25, 2025, 15:40 Hrs [IST] Biocon Biologics has announced that Yesintek (ust ...
Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients: Basel Tuesday, February 25, 2025, 14:00 Hrs [IST] Sandoz, the global leader in ge ...
YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.
Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available ...
Biocon Limited informed on Monday that its subsidiary Biocon Biologics announced the US market availability of YESINTEK ...
2don MSN
Biocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the United States for treating chronic autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results